SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies

This study is testing a specialized CAR-T cell therapy (engineered immune cells) for people with relapsed or treatment-resistant blood cancers that carry a marker called CD7. The cancers targeted include certain types of leukemia (T-ALL, AML) and other CD7-positive blood cancers. **You may be eligible if...** - You are between 18 and 70 years old - You have been diagnosed with relapsed or refractory T-ALL, AML, or another CD7-positive blood cancer - Your cancer cells are confirmed CD7-positive - You have at least 5% blast cells in the bone marrow - Your heart, kidneys, and liver function are within acceptable ranges - Your cancer has not responded to at least 2 rounds of standard chemotherapy, or has relapsed **You may NOT be eligible if...** - You have acute promyelocytic leukemia (a specific subtype) - You have an uncontrolled active central nervous system leukemia - You have a serious heart condition, recent heart attack, or severe arrhythmia - You have active uncontrolled infections - You are pregnant or breastfeeding - You have had prior allergy to cell therapy products - You have certain viral infections (hepatitis B/C, HIV, syphilis) - You have had uncontrolled graft-versus-host disease in the past month Talk to your doctor to see if this trial is right for you.